Therapeutic target for cognition enhancers: diagnosis and clinical phenomenology

Area of Science:

• Neuroscience
• Pharmacology
• Gerontology

Background:

• Drug development for cognitive enhancement is hindered by uncertainty regarding therapeutic targets.
• Regulatory approval pathways for cognition-enhancing drugs are unclear, especially for non-disease-specific applications.

Purpose of the Study:

• To explore the challenges and debates surrounding the development of cognition-enhancing drugs.
• To discuss potential therapeutic targets and trial design considerations for cognitive enhancement therapies.

Main Methods:

• Literature review and critical analysis of current approaches to cognitive enhancement drug development.
• Discussion of regulatory hurdles and the definition of appropriate clinical indications.

Main Results:

• Enhancement of normal cognitive function faces significant regulatory barriers.
• Targeting specific disease states (e.g., Alzheimer's) is less problematic than targeting normal aging or general syndromes like Age-Associated Memory Impairment (AAMI).

Conclusions:

• Clear clinical indications and well-defined patient populations are crucial for the approval of cognition-enhancing drugs.
• Future drug development should focus on specific disease states and employ rigorous diagnostic criteria for trial homogeneity.